Okumura Toshikatsu
Department of General Medicine, Asahikawa Medical College.
Nihon Rinsho. 2010 Feb;68(2):267-72.
Accumulating evidences have shown that thiazolidinediones (TZDs), PPARgamma ligands, could exert anti-cancer actions in several human cancer cells. TZDs are capable to inducing growth inhibition, apoptosis and inhibition of cell invasion, thereby leading to their anti-cancer effects. The growth inhibition was mediated by a cyclin-dependent kinase inhibitor, p27(Kip1), accumulation which is induced by both inhibition of ubiquitylation of p27(Kip1) and reduction of degradation activity of p27(Kip1) by proteasome. In addition, a recent clinical observation has showed a 33% reduction in lung cancer risk among TZD users who have diabetes mellitus compared with nonusers, strongly suggesting TZDs possess clinically relevant actions. These results suggest that TZDs may be novel agents to treat malignant tumor.
越来越多的证据表明，噻唑烷二酮类药物（TZDs），即过氧化物酶体增殖物激活受体γ（PPARγ）配体，可在多种人类癌细胞中发挥抗癌作用。TZDs能够诱导生长抑制、细胞凋亡并抑制细胞侵袭，从而产生抗癌效果。生长抑制是由细胞周期蛋白依赖性激酶抑制剂p27（Kip1）的积累介导的，这是通过抑制p27（Kip1）的泛素化以及蛋白酶体降低p27（Kip1）的降解活性来诱导的。此外，最近的一项临床观察表明，与未使用TZDs的糖尿病患者相比，使用TZDs的糖尿病患者患肺癌的风险降低了33%，这有力地表明TZDs具有临床相关作用。这些结果表明，TZDs可能是治疗恶性肿瘤的新型药物。
